Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 230 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger... February 19, 2020 Cancer in My Community: Addressing Regional Cancer Disparities in Peru August 24, 2023 How keeping active during cancer treatment has helped Mary and Keith September 26, 2022 Load more HOT NEWS For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer Νέα για τον καρκίνο του προστάτη
